Risk Factors for Term-Born Periventricular White Matter Injury in Children With Cerebral Palsy: A Case-Control Study.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
29 11 2022
Historique:
received: 10 02 2022
accepted: 05 08 2022
pubmed: 31 8 2022
medline: 1 12 2022
entrez: 30 8 2022
Statut: ppublish

Résumé

The aim of this study was to identify possible risk factors associated with term-born children with cerebral palsy (CP) and periventricular white matter injury (PVWMI) on imaging. This is a case-controlled study restricted to term-born children with CP with the cases extracted from the Canadian Cerebral Palsy Registry and controls from Alberta Pregnancy Outcomes and Nutrition (APrON) study. A diagnosis of PVWMI was performed based on expert categorization of MRI reports. Risk factor variables were selected a priori; these included pregnancy complications, antenatal toxin exposure, perinatal infection, sex, small for gestational age, and perinatal adversity (i.e., neonatal encephalopathy presumably on the basis of intrapartum hypoxia-ischemia). We used multivariable analyses to calculate odds ratios (ORs) and their 95% CIs. A total of 160 cases (7.06% of the registry sample) were compared with 1,950 controls. Of the term-born PVWMI participants, 59.4% were male and 13.5% were born to mothers of extreme maternal age. Multivariable analysis of each risk factor controlled for weight showed PVWMI is associated with pregnancy complications (OR = 3.35; 95% CI = 2.23-4.94), antenatal toxin exposure (OR = 2.45; 95% CI = 1.67-3.55), perinatal infection (OR = 3.61; 95% CI = 1.96-6.29), and perinatal adversity (OR = 2.03; 95% CI = 1.42-2.94). Term-born male participants were not more likely to experience PVWMI compared with female participants (OR = 1.37; 95% CI = 0.98-1.93). Multiple regression analyses suggested independent associations between PVWMI and pregnancy complications (OR = 3.75; 95% CI 2.46-5.62), antenatal toxin exposure (OR = 2.80; 95% CI 1.88-4.12), perinatal infection (OR = 4.62; 95% CI 2.46-8.42), and perinatal adversity (OR = 2.49; 95% CI = 1.71-3.69). Risk factors such as pregnancy complications, antenatal toxin exposure, perinatal infection, and perinatal adversity are associated with PVWMI in term-born children, suggesting perhaps variable interactions between antenatal and perinatal factors to yield this under-recognized CP phenotype.

Identifiants

pubmed: 36041870
pii: WNL.0000000000201274
doi: 10.1212/WNL.0000000000201274
pmc: PMC9728037
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2485-e2493

Informations de copyright

© 2022 American Academy of Neurology.

Références

Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23235-23241
pubmed: 32967067
Acta Neuropathol. 2005 Dec;110(6):563-78
pubmed: 16244891
Mol Genet Metab. 2020 Dec 29;:
pubmed: 33423928
N Engl J Med. 2006 Aug 17;355(7):685-94
pubmed: 16914704
Dev Med Child Neurol. 1995 May;37(5):379-97
pubmed: 7768338
Front Pediatr. 2021 Aug 02;9:683138
pubmed: 34408995
Paediatr Child Health. 2018 Jul;23(4):285-291
pubmed: 30657134
Pediatr Res. 2007 Apr;61(4):467-73
pubmed: 17515873
Pediatr Neurol. 2006 Mar;34(3):212-8
pubmed: 16504791
Lancet Neurol. 2009 Jan;8(1):110-24
pubmed: 19081519
J Pediatr. 2012 Jan;160(1):165-8.e1
pubmed: 21982304
Neuropediatrics. 1992 Feb;23(1):46-8
pubmed: 1565218
J Paediatr Child Health. 2000 Apr;36(2):139-44
pubmed: 10760012
Acta Neuropathol. 2017 Sep;134(3):331-349
pubmed: 28534077
Acta Paediatr. 2005 Mar;94(3):287-94
pubmed: 16028646
Neuroepidemiology. 2013;40(4):264-8
pubmed: 23363886
AJNR Am J Neuroradiol. 1992 Jan-Feb;13(1):67-78
pubmed: 1595496
Semin Perinatol. 2006 Apr;30(2):81-8
pubmed: 16731282
N Engl J Med. 2005 Oct 13;353(15):1574-84
pubmed: 16221780
J Thorac Cardiovasc Surg. 2014 Apr;147(4):1312-8
pubmed: 23879933
Arch Dis Child Fetal Neonatal Ed. 2008 Mar;93(2):F153-61
pubmed: 18296574
Matern Child Nutr. 2014 Jan;10(1):44-60
pubmed: 22805165
Semin Pediatr Neurol. 2013 Jun;20(2):60-4
pubmed: 23948680
Epilepsy Curr. 2020 Dec 3;21(1):27-29
pubmed: 34025269
Arch Neurol. 2008 Oct;65(10):1291-5
pubmed: 18852342
Dev Med Child Neurol. 1997 Jun;39(6):369-72
pubmed: 9233360
J Perinatol. 2017 Aug;37(8):963-968
pubmed: 28300820
Epilepsia. 2019 Oct;60(10):2086-2094
pubmed: 31541464
Ann Neurol. 1999 Nov;46(5):755-60
pubmed: 10553993
Pediatr Neurol. 2000 Aug;23(2):155-9
pubmed: 11020641
J Child Neurol. 2018 Apr;33(5):333-339
pubmed: 29464974
Neurology. 1999 Jan 15;52(2):341-5
pubmed: 9932954
J Thorac Cardiovasc Surg. 2004 Mar;127(3):692-704
pubmed: 15001897
Dev Med Child Neurol. 2007 Sep;49(9):700-6
pubmed: 17718828
Neurology. 2010 Apr 27;74(17):1386-91
pubmed: 20421583
Dev Med Child Neurol. 2021 Feb;63(2):144-155
pubmed: 33094492
Neuroradiology. 1990;32(3):187-90
pubmed: 2215901
Child Dev. 2010 Jan-Feb;81(1):6-22
pubmed: 20331651
Dev Med Child Neurol. 2005 Aug;47(8):571-6
pubmed: 16108461
Exp Ther Med. 2015 Apr;9(4):1336-1344
pubmed: 25780432

Auteurs

Amaar Marefi (A)

From the Department of Neurology & Neurosurgery (A.M., N.H., M.O., M.I.S.), McGill University; Department of Pediatrics (M.D.,), Alberta Children's Hospital, University of Calgary, Departments of Pediatrics and Clinical Neurosciences (M.D., A.K.), University of Calgary; Alberta Children's Hospital Research Institute (N.L., A.K.), University of Calgary; Departments of Pediatrics and Community Health Sciences (N.L.), University of Calgary; Faculty of Nursing and Department of Psychiatry (N.L.), University of Calgary; and Centre for Outcomes Research and Evaluation (M.O.), Research Institute of the McGill University Health Center, Montréal, Quebec, Canada.

Nafisa Husein (N)

From the Department of Neurology & Neurosurgery (A.M., N.H., M.O., M.I.S.), McGill University; Department of Pediatrics (M.D.,), Alberta Children's Hospital, University of Calgary, Departments of Pediatrics and Clinical Neurosciences (M.D., A.K.), University of Calgary; Alberta Children's Hospital Research Institute (N.L., A.K.), University of Calgary; Departments of Pediatrics and Community Health Sciences (N.L.), University of Calgary; Faculty of Nursing and Department of Psychiatry (N.L.), University of Calgary; and Centre for Outcomes Research and Evaluation (M.O.), Research Institute of the McGill University Health Center, Montréal, Quebec, Canada.

Mary Dunbar (M)

From the Department of Neurology & Neurosurgery (A.M., N.H., M.O., M.I.S.), McGill University; Department of Pediatrics (M.D.,), Alberta Children's Hospital, University of Calgary, Departments of Pediatrics and Clinical Neurosciences (M.D., A.K.), University of Calgary; Alberta Children's Hospital Research Institute (N.L., A.K.), University of Calgary; Departments of Pediatrics and Community Health Sciences (N.L.), University of Calgary; Faculty of Nursing and Department of Psychiatry (N.L.), University of Calgary; and Centre for Outcomes Research and Evaluation (M.O.), Research Institute of the McGill University Health Center, Montréal, Quebec, Canada.

Deborah Dewey (D)

From the Department of Neurology & Neurosurgery (A.M., N.H., M.O., M.I.S.), McGill University; Department of Pediatrics (M.D.,), Alberta Children's Hospital, University of Calgary, Departments of Pediatrics and Clinical Neurosciences (M.D., A.K.), University of Calgary; Alberta Children's Hospital Research Institute (N.L., A.K.), University of Calgary; Departments of Pediatrics and Community Health Sciences (N.L.), University of Calgary; Faculty of Nursing and Department of Psychiatry (N.L.), University of Calgary; and Centre for Outcomes Research and Evaluation (M.O.), Research Institute of the McGill University Health Center, Montréal, Quebec, Canada.

Nicole Letourneau (N)

From the Department of Neurology & Neurosurgery (A.M., N.H., M.O., M.I.S.), McGill University; Department of Pediatrics (M.D.,), Alberta Children's Hospital, University of Calgary, Departments of Pediatrics and Clinical Neurosciences (M.D., A.K.), University of Calgary; Alberta Children's Hospital Research Institute (N.L., A.K.), University of Calgary; Departments of Pediatrics and Community Health Sciences (N.L.), University of Calgary; Faculty of Nursing and Department of Psychiatry (N.L.), University of Calgary; and Centre for Outcomes Research and Evaluation (M.O.), Research Institute of the McGill University Health Center, Montréal, Quebec, Canada.

Maryam Oskoui (M)

From the Department of Neurology & Neurosurgery (A.M., N.H., M.O., M.I.S.), McGill University; Department of Pediatrics (M.D.,), Alberta Children's Hospital, University of Calgary, Departments of Pediatrics and Clinical Neurosciences (M.D., A.K.), University of Calgary; Alberta Children's Hospital Research Institute (N.L., A.K.), University of Calgary; Departments of Pediatrics and Community Health Sciences (N.L.), University of Calgary; Faculty of Nursing and Department of Psychiatry (N.L.), University of Calgary; and Centre for Outcomes Research and Evaluation (M.O.), Research Institute of the McGill University Health Center, Montréal, Quebec, Canada.

Adam Kirton (A)

From the Department of Neurology & Neurosurgery (A.M., N.H., M.O., M.I.S.), McGill University; Department of Pediatrics (M.D.,), Alberta Children's Hospital, University of Calgary, Departments of Pediatrics and Clinical Neurosciences (M.D., A.K.), University of Calgary; Alberta Children's Hospital Research Institute (N.L., A.K.), University of Calgary; Departments of Pediatrics and Community Health Sciences (N.L.), University of Calgary; Faculty of Nursing and Department of Psychiatry (N.L.), University of Calgary; and Centre for Outcomes Research and Evaluation (M.O.), Research Institute of the McGill University Health Center, Montréal, Quebec, Canada.

Michael I Shevell (MI)

From the Department of Neurology & Neurosurgery (A.M., N.H., M.O., M.I.S.), McGill University; Department of Pediatrics (M.D.,), Alberta Children's Hospital, University of Calgary, Departments of Pediatrics and Clinical Neurosciences (M.D., A.K.), University of Calgary; Alberta Children's Hospital Research Institute (N.L., A.K.), University of Calgary; Departments of Pediatrics and Community Health Sciences (N.L.), University of Calgary; Faculty of Nursing and Department of Psychiatry (N.L.), University of Calgary; and Centre for Outcomes Research and Evaluation (M.O.), Research Institute of the McGill University Health Center, Montréal, Quebec, Canada. michael.shevell@muhc.mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH